Loading
Latest filing published 17 Aug 2022 for Turning Point Therapeutics, Inc., €2.2M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Paolo Tombesi (finance chief) discloses dealings in Turning Point Therapeutics, Inc. to SEC (Form 4). In total, 4 filings cover trades dated from 26 July 2021 to 17 August 2022.
The open-market record consists of 1 sale worth €87k, with no purchase. Besides market trades, the filings include 2 share grants. So far in 2022, the count stands at no purchases and 1 sale.
The latest filing, published on 17 August 2022, reports a transaction of €2.2M in Turning Point Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations